The DIVERSITY1 Study for Crohn’s disease

If you have Crohn's disease and continue to experience symptoms, the DIVERSITY1 clinical research study may be for you.

Our team of medical professionals are evaluating an oral investigational drug to see if it reduces the signs and symptoms of Crohn’s disease by lowering the immune response that causes inflammation in the digestive system.

Complete our brief prescreening form to see if you may qualify or learn more about the study below.

Has Crohn’s disease ever ruined your day?

See if you may qualify for the study

About the Study

Diversity and Selection

The DIVERSITY1 study is evaluating an oral investigational drug for people with moderate to severe Crohn’s disease. The investigational drug is taken as a tablet once a day. This clinical research study will help determine if the investigational drug improves the signs and symptoms of Crohn’s disease.

What does the study involve?

  • The study will consist of 14 to 21 visits. The visits are one to eight weeks apart, over a period of approximately 58 weeks (about one year).
  • During the study, you may be able to continue some of your current drugs in addition to the investigational study drug. Continuation of current drugs will need to be discussed with the study doctor.
  • In addition to your current drugs, people in this study may receive the investigational drug or placebo (an inactive substance that looks like the investigational study drug).
    • Everyone who enrolls will be randomly assigned to receive one of two doses of the investigational drug or placebo (an inactive substance).
    • Neither you nor the study doctor will know whether you are taking active investigational drug or placebo.
    • Two out of three participants will receive active investigational drug during the initial 10 weeks of the study. If you respond favorably to the investigational study drug during this period, you will move on to the next stage at week 11.
    • At week 11, two out of three participants assigned to receive active investigational drug will continue to receive it for the remainder of the study. One in three will move to placebo, and participants already taking placebo who are responding favorably will remain on it.
  • Participants whose symptoms get worse after 10 weeks in the study may be eligible to receive active investigational drug in a separate long-term extension study.

Participants who complete the DIVERSITY1 study may have the opportunity to enroll in a long-term extension study in which they will continue to receive the investigational study drug they have been assigned.

More information about the DIVERSITY1 study can also be found at clinicaltrials.gov.

Ever miss the winning goal due to Crohn’s disease?

See if you may qualify for the study

Why should I participate?

Participants may:
  • Try an oral investigational drug to see if it reduces the signs and symptoms of Crohn’s disease
  • Receive investigational study drug and monitoring from a local study doctor
  • Be eligible to participate in a long-term extension study

Could I qualify?

Participants must:
  • Be currently experiencing symptoms such as diarrhea, with or without blood, or abdominal pain
  • Have been diagnosed with Crohn’s disease
  • Be 18 to 75 years of age
  • Meet eligibility criteria during screening at a participating doctor’s office

If you meet the criteria based on your responses to our prescreening form, you will be able to provide your contact information to a local doctor conducting the study. Their staff will answer any questions and will further determine if you may qualify.
However, only the investigational study drug will be provided. Other drugs you are currently taking for your Crohn’s disease or for other conditions will not be paid for by the study.

Does Crohn’s make you feel like you’re missing out on everyday activities?

See if you may qualify for the study

Educational Videos

Watch to learn more about Crohn's disease, clinical research, and the DIVERSITY1 study.
About Crohn's Disease

Crohn’s disease is a disorder of the immune system that causes the digestive system to become inflamed. People with Crohn's disease may experience diarrhea, abdominal pain, and weight loss, among other symptoms. Crohn's disease is also linked to a higher risk of other intestinal complications.

About Clinical Studies

Doctors use clinical studies to test drug safety and how well an investigational drug works for a specific condition. In a clinical study, participants may receive investigational drugs that have not yet been approved by the local regulatory agency. Researchers perform tests and assessments to find out how people respond to the investigational drug.

About the DIVERSITY1 Study

The DIVERSITY1 study is evaluating a once-daily oral investigational drug to see if it reduces the signs and symptoms of Crohn’s disease. People who participate in the DIVERSITY1 study may have access to the investigational study drug and study-related care from a local study doctor.

Has Crohn’s disease ever changed your destination?

See if you may qualify for the study

Clinical research studies are conducted to determine if potential new drugs are safe and whether they work. Clinical research studies are performed according to government regulations that help protect the safety and rights of the study participants.

A clinical investigator is a medical researcher in charge of conducting a clinical study and ensuring the well-being of study volunteers. The investigators conducting the DIVERSITY1 clinical study are all qualified licensed physicians and medical specialists.

An investigational drug, or research study drug, is a drug that has not yet been approved by the local country regulatory agency for prescription by doctors.

Yes, participation in any clinical research study is completely voluntary. If you decide to stop participating at any time, your exit will not affect the medical care you would otherwise receive.

Informed consent is the process of learning the key facts and details about a clinical research study. This information will be provided to you before you decide to participate, and as new information becomes available during your continued participation throughout the study. Once you have read the informed consent form and understand the details, including the risks and any potential benefits, you can decide whether or not to sign the document. The informed consent process also includes opportunities for you to ask questions about the study. No study-related procedures will take place without a signed informed consent form.

Information about your personal health will be kept private and confidential in an encrypted database in France by the company hosting this website, Neonstone Ltd. With your permission, the medical history and health condition information you provide via the prescreening form on this website about your medical history and health condition will be transferred to the study doctor’s office. A representative from the study doctor’s office will contact you to further determine your interest and eligibility. Your personal information will not be disclosed to anyone outside of this clinical research study group without your consent unless disclosure is required by law or regulations of the FDA, EMA, or similar local country regulatory agencies.

After answering the questions in the prescreening form, you will also have the option to sign up for future updates to be notified about other Crohn's disease studies. Respondents who do not qualify for the DIVERSITY1 study, or who are unable to locate a convenient site, will also be able to opt-in for updates. If you opt to receive these updates, you may receive emails from us in the future and may unsubscribe at any time.

This clinical study is being conducted to find out whether the investigational drug is effective in treating the signs and symptoms of Crohn’s disease.

Your answers to the questions in the online prescreening form will determine if you meet certain key criteria that are required to participate in the DIVERSITY1 study. If you meet these criteria, you can provide your contact information to the participating doctor’s office of your choice via our website. Their staff will then answer any questions you may have and will discuss the next steps to further determine whether you meet all of the criteria for participation. Not everyone who completes the online prescreening form will be able to participate in this study.

If you meet the criteria in the prescreening form, the staff at the doctor’s office will ask you to review and sign an informed consent form that explains more about the study. Then the staff at the doctor’s office will ask more questions and run some medical tests to see if you meet all eligibility criteria to participate in the clinical research study.

If you qualify for the DIVERSITY1 study, you will come to the study doctor’s office for periodic visits for study exams to evaluate your general health and to discuss your Crohn’s disease.

Feel free to discuss your study-related medical care with the study doctor or staff at any time during the course of the research study. It is important to take the investigational study drug as prescribed. You will answer questions regarding how you feel during your participation and whether the investigational study drug has been taken at the appropriate times. Participants are encouraged to discuss study participation with their general practitioner.

The study consists of 14 to 21 visits. The visits are one to eight weeks apart, over a period of approximately 58 weeks (about one year).

Approximately 1,320 people worldwide will be enrolled in the DIVERSITY1 study. This study is looking for people who have moderate to severe active Crohn's disease.

If you participate, study-related doctors’ visits, monitoring of your condition, and the investigational study drug will be provided to you. Other drugs you may be taking for your Crohn’s disease will not be paid for. The study staff at the participating site will be able to answer any questions you may have. Participants are encouraged to discuss study participation with their general practitioner.

The choice to participate in this study is entirely yours. Your primary care doctor does not have to give his or her permission or a referral for you to participate in this study. However, you should tell your primary care physician about your participation and keep him or her informed about the study. You should also keep the study doctor informed if your primary care physician changes your Crohn's disease treatment or if there are other changes to your health during the study.

A long-term extension study is a clinical study that allows participants to continue on the investigational study drug after they have finished their participation in the original study. After completion of the DIVERSITY1 study, participants may have the opportunity to enroll in a long-term extension study of the investigational drug in Crohn’s disease.

A placebo looks the same as the investigational study drug but does not contain any active ingredients. The use of a placebo is important in clinical research studies because it helps researchers determine how well the active investigational study drug is working.

Some people who participate in the DIVERSITY1 study will receive the active investigational study drug and some will receive a placebo. Neither you nor the study doctor will be able to choose or know which study group you are in. However, the study doctor can access this information if there is an emergency or if it is necessary to know for your health.

You could experience side effects associated with the investigational study drug. The study staff will discuss the known risks in detail with you before you decide whether or not to participate.

After a clinical study is complete, all of the information is collected and analyzed to help determine the investigational drug’s safety and efficacy. Please consult with your study doctor or primary healthcare provider to determine your treatment options after completing the study.

The DIVERSITY1 study is being conducted by trained, qualified, and licensed medical doctors worldwide.

Gilead Sciences, Inc. and Galapagos NV are developing the investigational study drug and sponsoring this clinical research study. GILEAD is a trademark of Gilead Sciences, Inc. All other trademarks referenced in this document are the property of their respective owners.